Opioid and other drug use and drug-related mortality as indicators of Hepatitis C and Human Immunodeficiency Virus in Oklahoma

被引:0
|
作者
Wendelboe, Aaron M. [1 ]
Naqvi, Ozair H. [1 ]
Williams, Mary [1 ]
Hollen, Heather [1 ]
McGrew, Kaitlin [2 ]
Li, Peng [2 ]
Harris, Terrainia [2 ]
Chou, Ann F. [3 ]
机构
[1] Univ Oklahoma, Hudson Coll Publ Hlth, Dept Biostat & Epidemiol, Hlth Sci Ctr, Oklahoma City, OK 73104 USA
[2] Oklahoma State Dept Hlth Sexual Hlth & Harm Reduct, Oklahoma City, OK USA
[3] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Family & Prevent Med, Oklahoma City, OK USA
来源
PLOS ONE | 2024年 / 19卷 / 05期
关键词
UNITED-STATES; INJECT DRUGS; HIV; VULNERABILITY; OXYMORPHONE; EPIDEMIC; INDIANA; HCV;
D O I
10.1371/journal.pone.0301442
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objectives Outbreaks of injection drug use (IDU)-associated infections have become major public health concerns in the era of the opioid epidemic. This study aimed to (1) identify county-level characteristics associated with acute HCV infection and newly diagnosed IDU-associated HIV in Oklahoma and (2) develop a vulnerability index using these metrics.Methods This study employs a county-level ecological design to examine those diagnosed with acute or chronic HCV or newly diagnosed IDU-associated HIV. Poisson regression was used to estimate the association between indicators and the number of new infections in each county. Primary outcomes were acute HCV and newly diagnosed IDU-associated HIV. A sensitivity analysis included all HCV (acute and chronic) cases. Three models were run using variations of these outcomes. Stepwise backward Poisson regression predicted new infection rates and 95% confidence intervals for each county from the final multivariable model, which served as the metric for vulnerability scores.Results Predictors for HIV-IDU cases and acute HCV cases differed. The percentage of the county population aged 18-24 years with less than a high school education and population density were predictive of new HIV-IDU cases, whereas the percentage of the population that was male, white, Pacific Islander, two or more races, and people aged 18-24 years with less than a high school education were predictors of acute HCV infection. Counties with the highest predicted rates of HIV-IDU tended to be located in central Oklahoma and have higher population density than the counties with the highest predicted rates of acute HCV infection.Conclusions There is high variability in county-level factors predictive of new IDU-associated HIV infection and acute HCV infection, suggesting that different public health interventions need to be tailored to these two case populations.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] PREVALENCE OF HUMAN IMMUNODEFICIENCY VIRUS AND HEPATITIS MARKERS IN PARENTERAL DRUG-ABUSERS
    UKENA, TE
    GULKIN, SL
    ESBER, HJ
    CLINICAL CHEMISTRY, 1988, 34 (06) : 1204 - 1204
  • [42] Missed opportunities for prevention: prevalence and incidence of human immunodeficiency virus and hepatitis C virus diagnoses among a cohort of individuals discharged from an urban hospital with injection drug-related diagnoses, 2012-2019
    Evans, Kimberly N.
    Vettese, Theresa
    Wortley, Pascale M.
    Gandhi, Ami P.
    Bradley, Heather
    ANNALS OF EPIDEMIOLOGY, 2023, 80 : 69 - +
  • [43] Anti-Tuberculosis Drug-Related Liver Injury in Chronic Hepatitis C Carriers
    Huang, Yi-Shin
    GASTROENTEROLOGY, 2009, 136 (05) : A820 - A821
  • [44] Improving Outcomes for People With Injection Drug-related Endocarditis: Are Medications for Opioid Use Disorder Enough?
    Kimmel, Simeon D.
    Del Rio, Carlos
    JOURNAL OF ADDICTION MEDICINE, 2020, 14 (04) : 280 - 281
  • [45] The effect of human immunodeficiency virus infection and drug use on birth characteristics
    Johnstone, FD
    Raab, GM
    Hamilton, BA
    OBSTETRICS AND GYNECOLOGY, 1996, 88 (03): : 321 - 326
  • [46] USE OF ZIDOVUDINE FOR DRUG MISUSERS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS - DISCUSSION
    MOXHAM, J
    ADLER, M
    MAW, R
    LANGE, J
    BURNS, DM
    CAREY, R
    JEFFRIES, D
    BIRD, A
    GRIFFITHS, PD
    PINCHING, A
    GAZZARD, B
    WELLER, I
    CLOAD, P
    JONES, P
    ELLIS, E
    DAWSON, S
    GREEN, S
    BECK, P
    JOURNAL OF INFECTION, 1989, 18 : 67 - 75
  • [47] Off-label drug use in human immunodeficiency virus disease
    Brosgart, CL
    Mitchell, T
    Charlebois, E
    Coleman, R
    Mehalko, S
    Young, J
    Abrams, DI
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1996, 12 (01): : 56 - 62
  • [48] Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug
    Lori, F
    Lisziewicz, J
    CLINICAL INFECTIOUS DISEASES, 2000, 30 : S193 - S197
  • [49] INJECTION-DRUG USE AND HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
    ALCABES, P
    FRIEDLAND, G
    CLINICAL INFECTIOUS DISEASES, 1995, 20 (06) : 1467 - 1479
  • [50] Hepatitis G virus infection in intravenous drug users with or without human immunodeficiency virus infection
    Campo, N
    Brizzolara, R
    Sinelli, N
    Puppo, F
    Campelli, A
    Indiveri, F
    Picciotto, A
    HEPATO-GASTROENTEROLOGY, 2000, 47 (35) : 1385 - 1388